Increased risk of maternal and neonatal complications in hormone replacement therapy cycles in frozen embryo transfer

Liping Zong1,2,3†, Peihao Liu1,2,3†, Liguang Zhou4, Daimin Wei1,2,3, Lingling Ding1,2,3 and Yingying Qin1,2,3*‡

Abstract

Background: The endometrial preparation during frozen embryo transfer (FET) can be performed by natural cycle (NC), hormone replacement therapy (HRT) cycle and cycle with ovulation induction (OI). Whether different FET preparation protocols can affect maternal and neonatal outcomes is still inconclusive.

Methods: This was a retrospective cohort study that included 6886 women who delivered singleton live birth babies after 28 weeks of pregnancy underwent FET from January, 2015 to July, 2018. Women were divided into three groups according to the protocols used for endometrial preparation during FET: NC group (N = 4727), HRT group (N = 1642) and OI group (N = 517).

Results: After adjusting for the effect of age, body mass index (BMI), irregular menstruation, antral follicle count (AFC), endometrial thickness, the levels of testosterone, anti-Müllerian hormone (AMH), preconceptional fasting glucose (PFG), systolic and diastolic pressure et al., the HRT group had higher risk of hypertensive disorders of pregnancy (HDP) compared with the NC group (adjusted odds ratio (aOR) 2.00, 95% confidence interval (CI) 1.54–2.60). Singletons born after HRT FET were at increased risk of low birth weight (LBW) compared to NC group (aOR 1.49, 95%CI 1.09–2.06). The risks of preterm birth (PTB) in the HRT and OI group were elevated compared with the NC group (aOR 1.78, 95%CI 1.39–2.28 and aOR 1.51, 95%CI 1.02–2.23, respectively).

Conclusions: The HRT protocol for endometrial preparation during frozen embryo transfer of blastocysts was associated with increased risk of maternal and neonatal complications, compared to the NC and OI protocol.

Keywords: Frozen embryo transfer, Endometrial preparation, Maternal and neonatal complications, Natural cycle, Hormone replacement therapy, Ovulation induction cycle

Introduction

In 1984, the success of first live birth after thawing the frozen human embryos was reported by the team of Zeilmaker [1]. Since then, the proportion of frozen embryo transfer (FET) has been increasing in in-vitro fertilization (IVF) along with the development of laboratory techniques for cryopreservation and the reduced number of embryo transfer in fresh cycle [2]. Recently, the so called “freeze-all strategy”, i.e. selectively freezing all embryos and performing FET later has become an optimal choice in cycles with high risk of ovarian hyper-stimulation syndrome (OHSS), preimplantation genetic testing (PGT) and double ovarian stimulation (DuoStim) protocols [3]. Several studies reported that FET achieved higher pregnancy rates and lower complications rates compared with fresh embryo transfer [4–6]. Therefore,
the “freeze-all strategy” has been widely used to improve live birth rates and decrease potential complications.

Multiple protocols for endometrium preparation have been explored during FET. The common protocols include natural cycles (NC), artificial cycle with hormone replacement therapy (HRT), and cycle with ovulation induction (OI) [7, 8]. Groenewoud et al. conducted a randomized controlled trial (RCT) concluding that HRT cycle was not inferior to modified natural cycle for FET with regard to live birth rates (LBRs), clinical and ongoing pregnancy rates [9]. The latest Cochrane review suggested there were no significant differences in pregnancy rates, miscarriage rates, or live birth rates among different endometrial preparation protocols for FET [7]. However, the effect of different protocols on maternal and neonatal outcomes is still uncertain. Here, we performed a retrospective study to compare the maternal and neonatal outcomes in women underwent NC, HRT, or OI protocol for endometrial preparation.

Materials and methods
Study design and participants
The study included 6886 women aged 20–40, who received FET treatment after IVF/ intracytoplasmic sperm injection (ICSI) cycles in Center for Reproductive Medicine, Shandong University from January, 2015 to July, 2018 and delivered singleton live birth baby after 28 weeks of pregnancy. These women were divided into three groups according to the endometrial preparation protocols: NC group (n = 4727), HRT group (n = 1642) and OI group (n = 517). Women with type II diabetes mellitus or preconceptional fasting glucose (PFG) ≥7.0 mmol/L, preconceptional hypertension, polycystic ovary syndrome (PCOS), uterine malformation and intrauterine adhesion were excluded. PCOS was defined as menstrual abnormalities (irregular uterine bleeding, oligomenorrhea, or amenorrhea) combined with either hyperandrogenism or polycystic ovaries [10]. PGT and oocyte donation cycles were also excluded. All blastocysts were vitrified on day 5 or day 6 according to the embryo development. (Fig. 1, Additional file 1: Table S1).

Endometrial preparation protocols for FET
In general, NC protocol was the preferred choice for women with regular menstruation. For patients with irregular menstruation or history of oligo-ovulation or anovulation, HRT or OI protocol was used as first choice.

In the NC group, transvaginal ultrasound was starting since day 10–12 of the menstrual cycle depending on the diameter of the follicle till ovulation. Urinary luteinizing hormone (LH) was tested combined with the ultrasound examination when the dominant follicle reached 14 mm in diameter. Human chorionic gonadotrophin (hCG, Le Baode, Livzon) was administrated to imitate the LH surge when the diameter of dominant follicle reaching 18 mm or more. Embryo transfer was scheduled 5 days after ovulation. Thirty mg oral dydrogesterone (Duphaston, Abbott Biologicals B.V.) was
administered daily from ovulation until the 12th week of pregnancy. In the HRT group, patients were prescribed with 4 mg oral estradiol valerate (Progynova, Delpharm Lille) since day 2–4 of menstruation for 5–6 days, and then 6 mg for the following 5–6 days. Endometrium thickness was monitored after 10–12 days of medication by transvaginal ultrasound along with the serum levels of LH, estradiol (E2) and progesterone (P). Thereafter the dose of estradiol valerate, which was 8 mg/d maximally, was modulated according to the endometrium thickness and the E2 levels. When the endometrium thickness reached at least 7 mm, FET was scheduled in 5 days. Dydrogesterone 40 mg/d and progesterone capsules (Utrogestan, Capsugel) 200 mg/d was given as luteal phase support until the 12th week of pregnancy. Meanwhile, 6 mg/d to 8 mg/d of estradiol valerate was continued until clinical pregnancy, which was defined as the presence of an intrauterine gestational sac by ultrasonography at 7–8 weeks of gestation.

In the OI group, 75 IU/d of human menopausal gonadotropin (HMG, Le Baode, Livzon) was started on day 3–5. Dose of HMG was adjusted according to the development of follicles as monitored on ultrasonography and the measurement of serum sex steroids. Urinary hCG was administrated at dose of 6000 IU to 8000 IU when one or two follicles reached 18 mm or more in diameter. One or two blastocysts were transferred. Maternal and neonatal complications including hypertensive disorders of pregnancy (HDP), gestational diabetes mellitus (GDM), placenta previa, oligohydramnios, preterm birth (PTB), low birth weight (LBW), small/large for gestational age (SGA/LGA) and gender of neonates were analyzed. HDP included gestational hypertension, pre-eclampsia, eclampsia and HELLP syndrome. GDM was diagnosed according to the 2013 WHO criteria (fasting plasma glucose ≥5.1 mmol/l; and/or 1 h plasma glucose ≥10.0 mmol/l; and/or 2 h plasma glucose ≥8.5 mmol/l after 24 weeks of gestation) [11]. Placenta previa referred to a placenta that lay in close proximity to the internal cervical os or may partially or completely cover it after 28 weeks of gestation. Oligohydramnios was defined as the single deepest pocket (SDP) ≤ 2 cm or amniotic fluid index (AFI) ≤ 5 cm. PTB was defined as delivery before 37 gestational weeks while not earlier than 28 gestational weeks [12]. LBW referred to birth weight of full-term delivered newborns below 2500 g. SGA was defined as birth weight below the 10th percentile referential birth weight; LGA was defined as birth weight higher than the 90th percentile referential birth weight [13].

### Statistical analysis

Continuous variables were summarized as the mean ± standard deviation and were compared by One-way ANOVA test. Chi-square test was used to compare the maternal and neonatal outcomes among the three groups. Multivariate logistic regression was performed to adjust for the effect of age, body mass index (BMI), irregular menstruation, the use of donor sperm, FET cycle number, number of transferred embryos, vanishing twin gestation, preconceptional fasting glucose (PFG), systolic pressure, diastolic pressure, endometrial thickness, antral follicle count (AFC), testosterone level, anti-Müllerian hormone (AMH) on HDP, PTB and LBW. Statistical significance level was set at 0.05. All statistical analyses were performed with SPSS (SPSS Inc., Version 21.0, Chicago, USA).

### Results

The number of women receiving NC, HRT and OI protocol for FET were 4727, 1642 and 517, respectively. The baseline characteristics were listed in Table 1. BMI (23.2 ± 3.4 vs. 22.8 ± 3.3 vs. 22.5 ± 3.2 kg/m², p < 0.001), AFC (15.6 ± 6.6 vs. 15.3 ± 6.0 vs. 14.9 ± 5.9, p < 0.001), and levels of testosterone (26.0 ± 11.9 vs. 25.6 ± 12.5 vs. 24.4 ± 11.7 ng/dL, p < 0.001) and AMH (5.3 ± 3.6 vs. 5.0 ± 3.5 vs. 4.7 ± 3.7 ng/mL, p < 0.001) were higher in HRT group compared to OI and NC group. As expected, HRT group and OI group had higher rates of irregular menstruation compared with NC group (21.9% vs. 21.7% vs. 5.6%, p < 0.001). Systolic pressure (120.8 ± 11.6 vs. 120.7 ± 11.9 vs. 119.5 ± 11.8, p < 0.001) and diastolic pressure (72.4 ± 8.6 vs. 73.3 ± 8.8 vs. 71.7 ± 8.7, p < 0.001) were higher in HRT and OI groups than NC group. And difference was also found in the FET cycle number among NC, HRT and OI groups (1.2 ± 0.5, 1.3 ± 0.6, 1.6 ± 0.8, p < 0.001). However, no difference was observed in the rate of donor sperm using (9.3% vs. 8.0% vs. 7.4%, p = 0.115) and vanishing twin gestation (3.0% vs. 3.2% vs. 2.5%, p = 0.710) among the three groups.

Table 2 listed the maternal and neonatal outcomes. For the maternal outcomes, women using HRT protocol had higher rates of HDP (7.9% in HRT vs. 4.6% in OI vs. 3.5% in NC, p < 0.001) than women in OI and NC group. Significant difference was observed in the rates of GDM among the three groups (6.5% in HRT vs. 7.5% in OI vs. 5.2% in NC, p = 0.030). The subgroup analyses showed that the GDM rate in OI group was higher than that in NC group, however, no difference existed between HRT group and NC group. The rates of placenta previa (1.5% in HRT vs. 1.2% in OI vs. 1.0% in NC, respectively, p = 0.299) and oligohydramnios (1.0% in HRT vs. 1.7% in OI vs. 1.3% in NC, respectively, p = 0.437) were similar among the three groups. For the neonatal outcomes (Table 2), HRT and OI groups had higher risk of PTB...
compared to NC group (7.9% in HRT vs. 4.6% in NC, \( p < 0.001 \) and 7.7% in OI vs. 4.6% in NC, \( p = 0.001 \)), but no significant difference was found between HRT and OI groups (7.9% vs. 7.7%, \( p = 0.773 \)). The HRT group had increased risk of LBW compared with the NC group (4.5% vs. 2.8%, \( p = 0.001 \)); however, no significant difference was observed between the OI group and the NC group (3.7% vs. 2.8%, \( p = 0.289 \)). In addition, different LGA risk was found among three groups (26.2% in HRT vs. 22.1% in OI vs. 23.4% in NC, \( p = 0.040 \)), although there was no significant difference between HRT and NC groups (\( p = 0.112 \)). Additionally, the three groups were comparable in terms of SGA risk (2.9% in HRT vs. 5.0% in OI vs. 3.5% in NC, \( p = 0.073 \)) and gender of neonates (\( p = 0.890 \)).

After adjusting for the effect of age, BMI, irregular menstruation, AFC, endometrial thickness, the levels of testosterone, AMH, PFG, systolic and diastolic pressure et al. (Table 3, Fig. 2), HRT group still showed higher risk of HDP (aOR 2.00, 95% CI 1.54–2.60) and LBW (aOR 1.49, 95%CI 1.09–2.06) compared with the NC group. Risk of PTB in the HRT and OI groups were elevated compared with NC group (aOR 1.78, 95%CI 1.39–2.28 and aOR 1.51, 95%CI 1.02–2.23, respectively).

The comparisons between IVF and ICSI cycles were listed in Additional file 2: Table S2-S13.

**Discussion**

In this study, we compared the maternal and neonatal outcomes of singletons born after FET with different
endometrial preparation protocols in a large cohort. A higher risk of HDP and LBW was observed in the HRT group, as well as increased risks of PTB in both HRT and OI group compared with NC group. The differences in the maternal and neonatal outcomes could be explained by the excessive estrogen exposure, absence of corpus luteum (CL) and distinct clinical characteristics of population in the HRT group.

During early pregnancy, the uterine spiral arteries transform from high-resistance, low-capacity to low-resistance, high-capacity vessels by trophoblasts immigrating, invading and replacing the endothelial and smooth muscle wall of the spiral arteries [14, 15]. The remodeling of the uterine spiral arteries is crucial for sufficient nutrient and oxygen supply from the placenta to the fetus through an optimal uteroplacental blood flow. Excessive estrogen levels have been reported to impair the invasion of trophoblastic vessels during pregnancy. In pregnant baboon, it has been shown that estrogen plays a major role in regulating morphological and functional differentiation of the villous trophoblasts and signals between the placenta and fetus. Moreover, an elevated estrogen level markedly suppressed the vascular invasion [16–18]. Attenuation of trophoblast vascular invasion and spiral artery restructure will result in placental defect, which subsequently interferes the pregnancy process and end up with complications such as hypertensive and growth disorders [19–23].

It has been evidenced that high levels of estrogen could increase the risks of maternal and neonatal outcome during IVF-ET treatment. Imudia et al. discovered that an elevated serum E2 concentration during controlled ovarian hyperstimulation (COH) was associated with higher risk of maternal preeclampsia and SGA newborns for fresh embryo transfer [24]. Pereira N et al. conducted a retrospective cohort study of 4071 patients undergoing fresh IVF-ET cycles, indicating that serum E2 levels exceeding 2500 pg/ml during COH seemed to be an independent predictor for LBW in full-term singletons [25]. Additionally, compared to FET, fresh embryo transferred showed worse obstetrical outcome, including LBW and PTB, which was also attributed to a hyperestrogenic milieu generated during ovarian stimulation [26–29].

During the preparation with HRT protocol, the patients were prescribed estrogen normally from 2 weeks before embryo transfer till 8th-10th week of pregnancy. It is assumed that the intake of exogenous estrogens during the period of trophoblastic vessels invasion may result in increased risk of maternal and neonatal complications, such as HDP and LBW. Study from Tatsumi et al. compared the pregnancy and neonatal outcomes among OI with letrozole cycle, natural cycle and HRT

### Table 2 Maternal and neonatal outcomes after FET in women with NC, HRT and OI group

| Maternal outcomes | NC | HRT | OI | P-value |
|-------------------|----|-----|----|---------|
| HDP, n. (%)       | 166 (3.5)<sup>a</sup> | 130 (7.9)<sup>b</sup> | 24 (4.6) | <0.001<sup>*</sup> |
| GDM, n. (%)       | 247 (5.2)<sup>b</sup> | 106 (6.5) | 39 (7.5) | 0.030<sup>+</sup> |
| Placenta previa, n. (%) | 47 (1.0) | 24 (1.5) | 6 (1.2) | 0.299 |
| Oligohydramnios, n. (%) | 61 (1.3) | 17 (1.0) | 9 (1.7) | 0.437 |

| Neonatal outcomes | <32 | 32–36<sup>+</sup> | ≥37 |
|-------------------|-----|-----------------|-----|
| Gestational age (weeks) | 39 (0.6)<sup>b</sup> | 18 (1.1) | 8 (1.5) | 0.023<sup>+</sup> |
| LBW, n. (%) | 130 (2.8)<sup>a</sup> | 74 (4.5) | 19 (3.7) | 0.002<sup>+</sup> |
| SGA, n. (%) | 165 (3.5) | 48 (2.9) | 26 (5.0) | 0.073 |
| LGA, n. (%) | 1104 (23.4) | 430 (26.2)<sup>c</sup> | 114 (22.1) | 0.040<sup>+</sup> |
| Gender of neonates n. (%) | 0.890<sup>+</sup> | |
| Male, n. (%) | 2500 (52.9) | 863 (52.6) | 278 (53.8) | |
| Female, n. (%) | 2227 (47.1) | 779 (47.4) | 239 (46.2) | |

FET frozen embryo transfer, NC natural cycle, HRT hormone replacement therapy, OI ovulation induction, HDP hypertensive disorders of pregnancy, GDM gestational diabetes mellitus, LBW low birth weight, SGA small for gestational age, LGA large for gestational age

<sup>*</sup> There were significant differences among the three groups
<sup>a</sup> There were significant differences between NC and HRT group
<sup>b</sup> There were significant differences between NC and OI group
<sup>c</sup> There were significant differences between HRT and OI group
cycle for FET and discovered differences in terms of gestational weeks at delivery, birth weight and SGA/LGA among three groups [30].

Another explanation for high risk of HDP in HRT protocol could be ascribed to the absence of corpus luteum (CL) in the first trimester when CL contributed most to hormone secretion. According to a recent study by von Versen-Höynck F, CL defect was associated with elevated rate of preeclampsia, which was probably caused by lack of circulating relaxin, a potent vasodilator secreted by CL yet not supplemented in the luteal phase support [31]. Another study also stressed that the vascular health was impaired when no CL was present during early pregnancy, which suggested an insufficient vascular adaption involved in the development of preeclampsia [32]. Ginström Ernstad E et al. conducted a population-based retrospective study in Sweden, in which FET cycles were grouped according to presence or absence of a CL [33]. His results demonstrated an increased risk of hypertensive disorders in HRT FET cycles, which was in accordance with our findings.

Thirdly, the increased risk of obstetric and neonatal complications in the HRT group was also caused by the distinct characteristics of the population. In our study, the preferred choice for endometrium preparation was NC protocol; while for patients with irregular menstruation or history of oligo-ovulation or anovulation, HRT or OI will be suggested. Although patients with PCOS had been excluded in the study, it was till reasonable to expect more women with endocrine disturbance in HRT and OI group than NC group. Not unexpectedly, compared to the NC group, women in HRT group had more AFC, higher BMI, and serum testosterone levels. Increased BMI and high levels of testosterone were involved in obstetrical complications through altered trophoblast invasion and placentation [34]. Obese patients were more likely to have dyslipidemia, which was associated with pregnancy complications and adverse pregnancy outcomes owing to vascular damage and endothelial dysfunction caused by oxidative stress from free radicals and lipid peroxides [34–36]. Hyperandrogenism and insulin resistance were also reported to alter endovascular trophoblast invasion and placentation [37–39]. Excess maternal androgens reduced placental weight and affected fetal growth in rats [40]. Therefore, the endocrine-metabolic disturbance in women using HRT protocol may also contributed to the adverse pregnancy outcomes.

Our sample size was large enough to detect the differences of maternal and neonatal complications in different groups as well as to adjust for the maternal characteristics. One of the limitations was the estradiol concentration during early pregnancy was unavailable thus the comparisons of estradiol level during pregnancy among different FET groups were lacking. Another problem was that since OI protocol was costlier and more time intensive for patient visiting compared to HRT protocol, patients in the OI group might tend to

| Table 3 Univariate and multivariate logistic regression model about NC, HRT and OI protocols |
|---------------------------------|----------------|-----|----------------|-----|
|                                | Crude OR (95% CI) | P-value | Adjusted OR (95% CI) | P-value |
| HDP                            |                |      |                      |      |
| NC                             | 1             | 1    |                       |      |
| HRT                            | 2.36 (1.86–2.99) | <0.001* | 2.00 (1.54–2.60) | <0.001* |
| OI                             | 1.34 (0.86–2.07) | 0.193 | 1.02 (0.62–1.65) | 0.853 |
| GDM                            |                |      |                      |      |
| NC                             | 1             | 1    |                       |      |
| HRT                            | 1.25 (0.99–1.58) | 0.061 | 1.10 (0.84–1.45) | 0.470 |
| OI                             | 1.48 (1.04–2.10) | 0.028* | 1.49 (0.97–2.19) | 0.056 |
| Placenta previa                |                |      |                      |      |
| NC                             | 1             | 1    |                       |      |
| HRT                            | 1.48 (0.90–2.42) | 0.122 | 1.52 (0.88–2.64) | 0.133 |
| OI                             | 1.17 (0.50–2.75) | 0.720 | 1.35 (0.55–3.27) | 0.514 |
| Oligohydramnios                |                |      |                      |      |
| NC                             | 1             | 1    |                       |      |
| HRT                            | 0.80 (0.47–1.37) | 0.419 | 0.70 (0.40–1.24) | 0.225 |
| OI                             | 1.36 (0.67–2.75) | 0.399 | 1.06 (0.49–2.29) | 0.887 |
| PTB                            |                |      |                      |      |
| NC                             | 1             | 1    |                       |      |
| HRT                            | 1.84 (1.47–2.30) | <0.001* | 1.78 (1.39–2.28) | <0.001* |
| OI                             | 1.76 (1.24–2.50) | 0.002* | 1.51 (1.02–2.23) | 0.041* |
| LBW                            |                |      |                      |      |
| NC                             | 1             | 1    |                       |      |
| HRT                            | 1.67 (1.25–2.23) | 0.001* | 1.49 (1.09–2.06) | 0.014* |
| OI                             | 1.35 (0.83–2.20) | 0.231 | 1.17 (0.70–1.96) | 0.547 |
| SGA                            |                |      |                      |      |
| NC                             | 1             | 1    |                       |      |
| HRT                            | 0.83 (0.60–1.15) | 0.271 | 0.85 (0.60–1.21) | 0.370 |
| OI                             | 1.46 (0.96–2.24) | 0.078 | 1.47 (0.94–2.31) | 0.092 |
| LGA                            |                |      |                      |      |
| NC                             | 1             | 1    |                       |      |
| HRT                            | 1.16 (1.02–1.33) | 0.021* | 1.15 (0.99–1.33) | 0.058 |
| OI                             | 0.93 (0.75–1.16) | 0.505 | 0.98 (0.77–1.24) | 0.842 |

NC natural cycle, HRT hormone replacement therapy, OI ovulation induction, OR odds ratio, CI confidence interval, HDP hypertensive disorders of pregnancy, GDM gestational diabetes mellitus, PTB preterm birth, LBW low birth weight, SGA small for gestational age, LGA large for gestational age

*There were significant differences between groups
have a history of thin endometrium or cancelled cycles which could lead to different maternal characteristics in this group.

**Conclusion**

Hormone replacement therapy protocol for frozen embryo transfer of blastocysts may be associated with adverse maternal and neonatal outcomes, such as high risks of HDP, LBW and PTB. Our results provide reference for endometrial preparation during FET treatment. More attention should be paid to the potential harmful effects of excessive estrogen and corpus luteum defect on maternal and neonatal complications during pregnancy.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s12958-020-00601-3.

**Additional file 1:** Table S1. Indications for frozen embryo transfer

**Additional file 2:** Table S2-S13. The comparisons between IVF and ICSI cycles in frozen embryo transfer.

**Abbreviations**

FET: Frozen embryo transfer; NC: Natural cycle; HRT: Hormone replacement therapy; OI: Ovulation induction; LBRs: Live birth rates; PFG: Preconceptional fasting glucose; PCOS: Polycystic ovary syndrome; HDP: Hypertensive disorders of pregnancy; GDM: Gestational diabetes mellitus; PTB: Preterm birth; LBW: Low birth weight; SGA: Small for gestational age; LGA: Large for gestational age; BMI: Body mass index; AFC: Antral follicle count; AMH: Anti-Müllerian hormone; CL: Corpus luteum; COH: Controlled ovarian hyperstimulation
Acknowledgements
The authors are grateful to physicians and coordinators who enrolled patients and collected data all women who participated in this study.

Authors’ contributions
LPZ, PHL, YYQ, contributed to the conception and design of the study; LLD, DMW, PHL were involved in acquisition of data collection; LPZ, PHL, LGZ analyzed data and drafted the manuscript. All authors revised the article and gave their final approval of the submitted version.

Funding
National Key Research & Developmental Program of China (2017YFC1001100), National Natural Science Foundation of China (81771541 and 817101404), Science Foundation for Distinguished Young Scholars of Shandong (JQ201720).

Availability of data and materials
The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was approved by the ethics committees of Reproductive Medical Center of Shandong University. Each patient has signed an informed consent on obtaining and analyzing their clinical data prior to the initiation of IVF/ICSI-ET treatment.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Center for Reproductive Medicine, Shandong University, No.157 Jingleiu Road, Jinan, China. 2. National Research Center for Assisted Reproductive Technology and Reproductive Genetics, Jinan, China. 3. The Key Laboratory of Reproductive Endocrinology (Shandong University) Ministry of Education, Jinan, China. 4. Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.

Received: 22 January 2020 Accepted: 24 April 2020
Published online: 04 May 2020

References
1. Zeilmaker GH, Alberda AT, van Gent I, Rijkmans CMPM, Drogendijk AC. Two pregnancies following transfer of intact frozen-thawed embryos. Fertil Steril. 1984;49:393–6.
2. Wong KM, Mastenbroek S, Repping S. Cryopreservation of human embryos and its contribution to in vitro fertilization success rates. Fertil Steril. 2014;102:19–26.
3. Maharshwari A, Pandey S, Shetty A, Hamilton M, Bhattacharya S. Obstetric and perinatal outcomes in singleton pregnancies resulting from in vitro fertilization treatment: a systematic review and meta-analysis. Fertil Steril. 2012;98:368–77.
4. Belva F, Henriet S, Van den Abbeel E, Camus M, Devroey P, Van der Elst J, et al. Neonatal outcome of 937 children born after transfer of cryopreserved embryos obtained by ICSI and IVF and comparison with outcome data of fresh ICSI and IVF cycles. Hum Reprod. 2008;23:2227–38.
5. Palomba S, Homburg R, Santagni S, La Sala GB, Orvieto R. Risk of adverse pregnancy and perinatal outcomes after high technology infertility treatment: a comprehensive systematic review. Reprod Biol Endocr. 2016;14:76.
6. Roque M, Lattes K, Serra S, Sola I, Geber S, Carrares M, et al. Fresh embryo transfer versus frozen embryo transfer in in vitro fertilization cycles: a systematic review and meta-analysis. Fertil Steril. 2013;99:156–62.
7. Ghobara T, Gelbaya TA, Ayeleke RO. Cycle regimens for frozen-thawed embryo transfer. Cochrane Database Syst Rev. 2017;7:CD003414.
8. Glujovsky D, Pesce R, Fiszboj G, Suelo C, Hart RJ, Caipponi A. Endometrial preparation for women undergoing embryo transfer with frozen embryos or embryos derived from donor oocytes. Cochrane Database Syst Rev. 2010;1:CD006359.
9. Groenewoud ER, Cohen BJ, Arols V, Brikhuus EA, Broekmans FJ, de Brum JP, et al. A randomized controlled, non-inferiority trial of modified natural versus artificial cycle for cryo-thawed embryo transfer. Hum Reprod. 2016;31:1483–92.
10. Endocrinology Subgroup and Expert Panel, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. Chinese guideline for diagnosis and management of polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi. 2018;53:2–6.
11. World Health Organization. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. Diabetes Res Clin Pract. 2013;103:341–63.
12. National Collaborating Centre for Women’s and Children’s Health (UK). Preterm labour and birth. UK: National Institute for Health and Care Excellence; 2015.
13. Dai L, Deng C, Li Y, Zhu J, Mu Y, Deng Y, et al. Birth weight reference percentiles for Chinese. Plos One. 2014;9:e104779.
14. Pijnenborg R, Bland JM, Robertson WB, Brosens I. Uteroplastic changes related to interstitial Trophoblast migration in human early pregnancy. Placenta. 1983;4:397–414.
15. Pijnenborg R, Vercruyse L, Hansens M. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta. 2006;27:939–58.
16. Albrecht ED, Bonagura TW, Burchill DW, Enders AC, Aberdeen GW, Pepe GJ. Suppression of extravillous trophoblast invasion of uterine spiral arteries by estrogen during early baboon pregnancy. Placenta. 2006;27:483–90.
17. Babischkin JS, Burchill DW, Mayhew TM, Pepe GJ, Albrecht ED. Developmental regulation of morphological differentiation of placental villous trophoblast in the baboon. Placenta. 2001;22:276–83.
18. Bonagura TW, Pepe GJ, Enders AC, Albrecht ED. Suppression of extravillous trophoblast vascular endothelial growth factor expression and uterine spiral artery invasion by estrogen during early baboon pregnancy. Endocrinology. 2008;149:5078–87.
19. Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by preeclampsia and by small-for-gestational-age infants. BIOG. 1986;93:1049–56.
20. Labarrere CAAD. Inadequate maternal vascular response to placentation in pregnancies complicated by preeclampsia and by small-for-gestational-age infants. BIOG. 1987;94:1113–6.
21. Pijnenborg RA, Davey DA, Rees A, Titman A, Vercruyse L, Assche A. Placental bed spiral arteries in the hypertensive disorders of pregnancy. BIOG. 1991;96:648–55.
22. Sheppard BL, Bonnar J. The ultrastructure of the arterial supply of the human placenta in pregnancy complicated by fetal growth retardation. BIOG. 1976;92:948–59.
23. Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu. 1972;1:177–91.
24. Imudia AN, Awonuga AO, Doyle JO, Kaimal AJ, Wright DL, Toth TL, et al. Peak serum estradiol level during controlled ovarian hyperstimulation is associated with increased risk of small for gestational age and preeclampsia in singleton pregnancies after in vitro fertilization. Fertil Steril. 2011;97:1374–9.
25. Pereira N, Elias RT, Christos PJ, Petrini AC, Hancock K, Lekovich JP, et al. Supraphysiologic estradiol is an independent predictor of low birth weight in full-term singletons born after fresh embryo transfer. Hum Reprod. 2017;32:1410–7.
26. Kalla SK, Ratcliffe SJ, Coutifaris C, Molinaro T, Barnhart KT. Ovarian stimulation and low birth weight in newborns conceived through in vitro fertilization. Obstet Gynecol. 2011;118:863–71.
27. Pekonen S, Kolvonen R, Gissler M, Nuujia-Huttunen S, Suikkari AM, Hyden-Granskog C, et al. Perinatal outcome of children born after frozen and fresh embryo transfer: the Finnish cohort study 1995–2006. Hum Reprod. 2010;25:914–20.
28. Pinborg A, Linde O, Henningsen K, Rasmussen S, Andersen AS. Infant outcome of 957 singletons born after frozen embryo replacement: the Danish National Cohort Study 1995–2006. Fertil Steril. 2010;94:1320–7.
29. Wennerholm UB, Henningsen AK, Romandsted LB, Bergh C, Pinborg A, Skjaerven R, et al. Perinatal outcomes of children born after frozen-thawed embryo transfer: a Nordic cohort study from the CoNARTaS group. Hum Reprod. 2013;28:2545–53.
30. Tatsumi T, Iwahara A, Ishihara M, Kubota T, Saito H. Pregnancy and neonatal outcomes following letrozole use in frozen-thawed single embryo transfer cycles. Hum Reprod. 2017;32:1244–8.

31. von Versen-Höynck F, Schaub AM, Chi YY, Chiu KH, Liu J, Lingis M, et al. Increased preeclampsia risk and reduced aortic compliance with in vitro fertilization cycles in the absence of a Corpus Luteum. Hypertension. 2019;73:640–9.

32. von Versen-Höynck F, Narasimhan P, Selamet Tierney ES, Martinez N, Conrad KP, Baker VL, et al. Absent or excessive Corpus Luteum number is associated with altered maternal vascular health in early pregnancy. Hypertension. 2019;73:680–90.

33. Ginstrom Emst ed, Wernerholm UB, Khatibi A, Petzold M, Bergh C. Neonatal and maternal outcome after frozen embryo transfer: Increased risks in programmed cycles. Am J Obstet Gynecol. 2019;221:126.e1–126.e18.

34. Palomba S, de Wilde MA, Falbo A, Koster MP, La Sala GB, Fauser BC. Pregnancy complications in women with polycystic ovary syndrome. Hum Reprod Update. 2015;21:57–92.

35. Jan MR, Nazli R, Shah J, Akhtar T. A study of lipoproteins in normal and pregnancy induced hypertensive women in tertiary care hospitals of the north west frontier province-Pakistan. Hypertens Pregnancy. 2012;31:292–9.

36. Vrijkotte TG, Kruiziener N, Hutten BA, Vollebregt KC, van Eijsden M, Twickler MB. Maternal lipid profile during early pregnancy and pregnancy complications and outcomes: the ABCD study. J Clin Endocrinol Metab. 2012;97:3917–25.

37. Palomba S, Marotta R, Di Cello A, Russo T, Falbo A, Orio F, et al. Pervasive developmental disorders in children of hyperandrogenic women with polycystic ovary syndrome: a longitudinal case-control study. Clin Endocrinol. 2012;77:989–904.

38. Palomba S, Russo T, Falbo A, Di Cello A, Amendola G, Mazza R, et al. Decidual endovascular trophoblast invasion in women with polycystic ovary syndrome: an experimental case-control study. J Clin Endocrinol Metab. 2012;97:2441–9.

39. Palomba S, Russo T, Falbo A, Di Cello A, Tolino A, Tucci L, et al. Macroscopic and microscopic findings of the placenta in women with polycystic ovary syndrome. Hum Reprod. 2013;28:2638–47.

40. Sun M, Maliqueo M, Benrick A, Johansson J, Shao R, Hou L, et al. Maternal androgen excess reduces placental and fetal weights, increases placental steroidogenesis, and leads to long-term health effects in their female offspring. Am J Physiol Endocrinol Metab. 2012;303:1373–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.